Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sunitinib Malate

FDA-approved product (capsule, oral), marketed as Sunitinib Malate, Sutent.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Sunitinib Malate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Clear cell renal carcinoma
  • Gastrointestinal stromal tumor
  • Neoplasm
  • Neuroendocrine neoplasm
  • Pancreatic neuroendocrine tumor
  • Papillary renal cell carcinoma
  • Renal cell adenocarcinoma
  • Renal cell carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sunitinib Malate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sunitinib Malate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • GIST Oral Paclitaxel(Liporaxel)

    NCT06326346 · start 2024-11-20

    Registered record
    Registry ID
    NCT06326346
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    Liporaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-11-20
    Completion
    2027-03-31
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionLiporaxel
    PhasePhase 2
    Registry statusRecruiting

  • Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC

    NCT06222593 · start 2024-10-01

    Registered record
    Registry ID
    NCT06222593
    Conditions
    Carcinoma, Renal Cell
    Interventions
    Bicalutamide in combination with Sunitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-10-01
    Completion
    2027-07-01
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Renal Cell
    InterventionBicalutamide in combination with Sunitinib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.

    NCT05745142 · start 2023-02-23

    Registered record
    Registry ID
    NCT05745142
    Conditions
    Carcinoma, Renal Cell; Clear-cell Metastatic Renal Cell Carcinoma
    Interventions
    Sunitinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-02-23
    Completion
    2023-02-23
    Enrolment
    376

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Renal Cell; Clear-cell Metastatic Renal Cell Carcinoma
    InterventionSunitinib
    PhaseNot recorded
    Registry statusCompleted

  • TARGETed Therapy Drug MONITOring in DIGestive Oncology

    NCT05443087 · start 2022-08-29

    Registered record
    Registry ID
    NCT05443087
    Conditions
    Digestive Cancer; Metastatic Colorectal Cancer; Hepatocellular Carcinoma; GIST; Neuroendocrine Tumors
    Interventions
    Blood sampling to build population pharmacokinetics model
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2022-08-29
    Completion
    2027-06
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDigestive Cancer; Metastatic Colorectal Cancer; Hepatocellular Carcinoma; GIST +1 more
    InterventionBlood sampling to build population pharmacokinetics model
    PhaseNot applicable
    Registry statusRecruiting

  • Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

    NCT05477576 · start 2022-03-24

    Registered record
    Registry ID
    NCT05477576
    Conditions
    GEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors; Carcinoid; Carcinoid Tumor; Pancreatic NET
    Interventions
    RYZ101; Everolimus; Sunitinib; Octreotide; Lanreotide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-03-24
    Completion
    2030-12
    Enrolment
    338

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGEP-NET; Gastroenteropancreatic Neuroendocrine Tumor; Gastroenteropancreatic Neuroendocrine Tumor Disease; Neuroendocrine Tumors +3 more
    InterventionRYZ101; Everolimus; Sunitinib; Octreotide +1 more
    PhasePhase 3
    Registry statusRecruiting

  • Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure

    NCT04193553 · start 2020-01-17

    Registered record
    Registry ID
    NCT04193553
    Conditions
    Gastro Intestinal Stromal Tumour
    Interventions
    Lenvatinib; Placebo; Best supportive care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-01-17
    Completion
    2024-04-26
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastro Intestinal Stromal Tumour
    InterventionLenvatinib; Placebo; Best supportive care
    PhasePhase 2
    Registry statusCompleted

  • Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib

    NCT03592199 · start 2017-12-11

    Registered record
    Registry ID
    NCT03592199
    Conditions
    Clear Cell Renal Cell Carcinoma
    Interventions
    Sunitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2017-12-11
    Completion
    2022-12-11
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClear Cell Renal Cell Carcinoma
    InterventionSunitinib
    PhasePhase 2
    Registry statusUnknown

  • The Pharmacokinetic Variability of Sunitinib in Patients With Metastatic Renal Cancer

    NCT02404584 · start 2015-12-29

    Registered record
    Registry ID
    NCT02404584
    Conditions
    Kidney Neoplasms
    Interventions
    Blood drawn for genotyping; Blood drawn for pharmacokinetic measures
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-12-29
    Completion
    2019-05-21
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Neoplasms
    InterventionBlood drawn for genotyping; Blood drawn for pharmacokinetic measures
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma

    NCT02623127 · start 2015-10

    Registered record
    Registry ID
    NCT02623127
    Conditions
    Thymic Carcinoma
    Interventions
    Sunitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-10
    Completion
    2018-10
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThymic Carcinoma
    InterventionSunitinib
    PhasePhase 2
    Registry statusCompleted

  • Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    NCT02465060 · start 2015-08-17

    Registered record
    Registry ID
    NCT02465060
    Conditions
    Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma; Cervical Carcinoma; Colon Carcinoma; Colorectal Carcinoma; Endometrial Carcinoma; Esophageal Carcinoma; Exocrine Pancreas Carcinoma; Gastric Carcinoma; Glioma; Head and Neck Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Kidney Carcinoma; Liver Carcinoma; Lung Carcinoma; Lymphoma; Malignant Uterine Corpus Neoplasm; Malignant Uterine Neoplasm; Melanoma; Multiple Myeloma; Ovarian Carcinoma; Prostate Carcinoma; Rectal Carcinoma; Recurrent Bladder Carcinoma; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Colon Carcinoma; Recurrent Colorectal Carcinoma; Recurrent Esophageal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Glioma; Recurrent Head and Neck Carcinoma; Recurrent Liver Carcinoma; Recurrent Lung Carcinoma; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Uterine Corpus Neoplasm; Recurrent Melanoma; Recurrent Multiple Myeloma; Recurrent O
    Interventions
    Adavosertib; Afatinib; Afatinib Dimaleate; Binimetinib; Biopsy Procedure; Biospecimen Collection; Capivasertib; Computed Tomography; Copanlisib; Copanlisib Hydrochloride; Crizotinib; Cytology Specimen Collection Procedure; Dabrafenib; Dabrafenib Mesylate; Dasatinib; Defactinib; Defactinib Hydrochloride; Echocardiography Test; Erdafitinib; Fexagratinib; Ipatasertib; Laboratory Biomarker Analysis; Larotrectinib; Larotrectinib Sulfate; Magnetic Resonance Imaging; Multigated Acquisition Scan; Nivolumab; Osimertinib; Palbociclib; Pertuzumab; PI3K-beta Inhibitor GSK2636771; Radiologic Examination; Radionuclide Imaging; Relatlimab; Sapanisertib; Sunitinib Malate; Taselisib; Trametinib; Trastuzumab; Trastuzumab Emtansine; Ulixertinib; Vismodegib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2015-08-17
    Completion
    2026-12-31
    Enrolment
    6,452

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma; Breast Carcinoma +38 more
    InterventionAdavosertib; Afatinib; Afatinib Dimaleate; Binimetinib +38 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Study of Muscle Energy Metabolism in RCC Patients Treated With Sunitinib

    NCT02428335 · start 2015-06

    Registered record
    Registry ID
    NCT02428335
    Conditions
    Renal Cell Cancer; Fatigue
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2015-06
    Completion
    2019-03-18
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Cancer; Fatigue
    InterventionNot recorded
    PhaseNot recorded
    Registry statusWithdrawn

  • Multiple Treatments for Ebola Virus Disease (EVD)

    NCT02380625 · start 2015-04

    Registered record
    Registry ID
    NCT02380625
    Conditions
    Ebola Virus Disease
    Interventions
    Azithromycin; Sunitinib and Erlotinib; Atorvastatin and Irbesartan; IV fluids and laboratory testing
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2015-04
    Completion
    2016-03
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEbola Virus Disease
    InterventionAzithromycin; Sunitinib and Erlotinib; Atorvastatin and Irbesartan; IV fluids and laboratory testing
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors

    NCT02401815 · start 2015-03-06

    Registered record
    Registry ID
    NCT02401815
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    CGT9486; Pexidartinib; Sunitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-03-06
    Completion
    2020-05-11
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionCGT9486; Pexidartinib; Sunitinib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

    NCT02068586 · start 2014-11-19

    Registered record
    Registry ID
    NCT02068586
    Conditions
    Ciliary Body and Choroid Melanoma, Medium/Large Size; Ciliary Body and Choroid Melanoma, Small Size; Iris Melanoma; Stage I Intraocular Melanoma; Stage IIA Intraocular Melanoma; Stage IIB Intraocular Melanoma; Stage IIIA Intraocular Melanoma; Stage IIIB Intraocular Melanoma; Stage IIIC Intraocular Melanoma; Stage I Uveal Melanoma AJCC V7; Stage II Uveal Melanoma AJCC V7; Stage III Uveal Melanoma AJCC V7
    Interventions
    Sunitinib; Valproic Acid; Sunitinib Malate; Sunitinib Malate + Valproic Acid
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2014-11-19
    Completion
    2026-12-31
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCiliary Body and Choroid Melanoma, Medium/Large Size; Ciliary Body and Choroid Melanoma, Small Size; Iris Melanoma; Stage I Intraocular Melanoma +8 more
    InterventionSunitinib; Valproic Acid; Sunitinib Malate; Sunitinib Malate + Valproic Acid
    PhasePhase 2
    Registry statusActive not recruiting

  • Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma

    NCT03519542 · start 2014-11

    Registered record
    Registry ID
    NCT03519542
    Conditions
    Metastatic Renal Cell Carcinoma
    Interventions
    Sunitinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-11
    Completion
    2018-07
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Renal Cell Carcinoma
    InterventionSunitinib
    PhaseNot recorded
    Registry statusCompleted